Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative therapies function by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these agents enhance insulin production and s

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing differences in their pharm